GraySpace Therapeutics
407-15 Innovation Boulevard S7N2X8 Saskatoon, SK, Canada

GraySpace is thrilled to have the opportunity to present at tomorrow's Landmark Virtual Forum, put on by the Landmark Angels Group. We will be discussing our revolutionary new approach to treating what we believe is the underlying metabolic cause of Alzheimer's disease. #alzheimers #alzheimersresearch #dementia #plasmalogen

In support of our Alzheimer's drug development program, GraySpace Therapeutics will be attending the 13th Clinical Trials in Alzheimer's Disease conference. https://grayspacetherapeutics.com//pib4l4u5hpur1fl7rub8yxy

We would love to meet you (virtually) at BioEurope later this month. We are developing a therapeutic to address an underlying metabolic deficiency increasingly believed to drive Alzheimer’s disease pathology. https://grayspacetherapeutics.com//pib4l4u5hpur1fl7rub8yxy

At GraySpace Therapeutics, we are seeking to develop a fundamentally new approach for the treatment of Alzheimer’s disease. For more information, visit our site below. https://grayspacetherapeutics.com/science

More than 5 million Americans are living with Alzheimer's disease and this is expected to reach ~14 million by 2050. In addition to the physical stress and emotional toll of the disease, the national cost of caring for people with dementia will be $305 billion this year.

Today is World Alzheimer’s Day and this year’s theme is: Let’s talk about dementia. Although globally over 50 million people are living with dementia, 2 out of 3 people believe there is little understanding of dementia in their countries and this year’s theme expresses the urgency needed to change this. For more information on Alzheimer’s disease and dementia visit https://www.alz.org/.